(Q38156139)

29 August 2017

Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence (English)

1 reference

allergic bronchopulmonary aspergillosis

29 August 2017

0 references

0 references

0 references

3

Athanasios G Kaditis

1 reference

29 August 2017

2

Elias Zintzaras

1 reference

29 August 2017

Kalliopi Tanou

1

1 reference

29 August 2017

25 October 2013

1 reference

29 August 2017

Pediatric Pulmonology

1 reference

29 August 2017

49

1 reference

29 August 2017

5

1 reference

29 August 2017

503-507

1 reference

Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference

29 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22937

Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22937

Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22937

Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22937

Omalizumab for exacerbations of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22937

Resolution of corticosteroid-induced diabetes in allergic bronchopulmonary aspergillosis with omalizumab therapy: a novel approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22937

Omalizumab in the management of steroid dependent allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22937

Omalizumab for treatment of ABPA exacerbations in CF patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22937

Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22937

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22937

21 January 2018

Identifiers

DOI

10.1002/PPUL.22937

1 reference

29 August 2017

1 reference

PubMed ID

24167019